These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 20019985)
1. The management of BCG failure in non-muscle-invasive bladder cancer: an update. Zlotta AR; Fleshner NE; Jewett MA Can Urol Assoc J; 2009 Dec; 3(6 Suppl 4):S199-205. PubMed ID: 20019985 [TBL] [Abstract][Full Text] [Related]
2. Definition and management of patients with bladder cancer who fail BCG therapy. Martin FM; Kamat AM Expert Rev Anticancer Ther; 2009 Jun; 9(6):815-20. PubMed ID: 19496718 [TBL] [Abstract][Full Text] [Related]
3. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer. Shepherd AR; Shepherd E; Brook NR Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259 [TBL] [Abstract][Full Text] [Related]
4. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428 [TBL] [Abstract][Full Text] [Related]
5. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra. Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432 [TBL] [Abstract][Full Text] [Related]
6. Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma. Yassaie O; Chehroudi C; Black PC Ther Adv Med Oncol; 2021; 13():17588359211039052. PubMed ID: 34408797 [TBL] [Abstract][Full Text] [Related]
7. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M; Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737 [TBL] [Abstract][Full Text] [Related]
9. The use of intravesical BCG in urothelial carcinoma of the bladder. Alhunaidi O; Zlotta AR Ecancermedicalscience; 2019; 13():905. PubMed ID: 30915163 [TBL] [Abstract][Full Text] [Related]
10. Management of high-risk non-muscle invasive bladder cancer. Brausi M; Olaru V Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212 [TBL] [Abstract][Full Text] [Related]
11. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. Lamm D; Brausi M; O'Donnell MA; Witjes JA Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309 [TBL] [Abstract][Full Text] [Related]
12. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder. Merz VW; Marth D; Kraft R; Ackermann DK; Zingg EJ; Studer UE Br J Urol; 1995 Feb; 75(2):180-4. PubMed ID: 7850322 [TBL] [Abstract][Full Text] [Related]
13. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843 [TBL] [Abstract][Full Text] [Related]
14. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924 [TBL] [Abstract][Full Text] [Related]
18. Bacillus Calmette-Guérin unresponsiveness in non-muscle-invasive bladder cancer patients: what the urologists should know. Moschini M; Zamboni S; Mattei A; Amparore D; Fiori C; De Dominicis C; Esperto F; Minerva Urol Nefrol; 2019 Feb; 71(1):17-30. PubMed ID: 30421598 [TBL] [Abstract][Full Text] [Related]
19. Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin. Steinberg RL; Thomas LJ; Nepple KG Urol Oncol; 2016 Jun; 34(6):279-89. PubMed ID: 26777259 [TBL] [Abstract][Full Text] [Related]
20. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. Packiam VT; Lamm DL; Barocas DA; Trainer A; Fand B; Davis RL; Clark W; Kroeger M; Dumbadze I; Chamie K; Kader AK; Curran D; Gutheil J; Kuan A; Yeung AW; Steinberg GD Urol Oncol; 2018 Oct; 36(10):440-447. PubMed ID: 28755959 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]